1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow Cardiac Dysfunction: new trials by email Literature Review of Cardiac Dysfunction trials Research Report on Cardiac Dysfunction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). Pemziviptadil (PB1046), Low Dose (10 mg) Control - Acute Respiratory Distress Syndrome, Coronavirus | Phase 2 | Terminated | PhaseBio Pharmaceuticals Inc. | 54 | 2020-07-15 | 2020-12-11 |
COVID-19 (1) · Cardiovascular Diseases (1) · Coronavirus Infections (1) · Cytokine Release Syndrome (1) · Dyspnea (1) · Heart Failure (1) · Myocardial Infarction (1) · Pneumonia (1) · Pulmonary Edema (1) · Respiratory Distress Syndrome (1) · Respiratory Insufficiency (1)
Coronaviridae Infections (1) · Heart Diseases (1) · Infarction (1) · Infections (1) · Inflammation (1) · Ischemia (1) · Lung Diseases (1) · Myocardial Ischemia (1) · Necrosis (1) · Nidovirales Infections (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Pneumonia, Viral (1) · RNA Virus Infections (1) · Respiration Disorders (1)
VIP-ELP fusion molecule PB1046 (1)
PhaseBio Pharmaceuticals Inc. (1)
United States (1)